{"nctId":"NCT01401595","briefTitle":"Brain Imaging and Treatment Studies of the Night Eating Syndrome","startDateStruct":{"date":"2009-12"},"conditions":["Night Eating Syndrome"],"count":87,"armGroups":[{"label":"Night Eaters","type":"EXPERIMENTAL","interventionNames":["Drug: escitalopram oxalate"]},{"label":"Control Subjects","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"escitalopram oxalate","otherNames":["Lexapro"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* men and women suffering from NES\n* ages 18 to 70 years\n* BMI greater than 18.5 kg/m2\n\nExclusion Criteria:\n\n* Children or adolescents \\<18 years\n* persons older than 70\n* patients with diabetes mellitus\n* thyroid disease and other endocrine and metabolic disorders\n* use within the past month of any psychotropic medication, oral steroids, diuretics or hypnotics\n* current anorexia nervosa or bulimia nervosa\n* participation in an organized weight reduction program\n* use of antiobesity medication\n* an occupation that involves night shifts or other unusual time requirements -Major Depressive Disorder (judged severe)\n* Bipolar Disorder\n* suicidal risk\n* current or past psychosis\n* substance use or abuse disorder within the past 6 months","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Symptoms of NES","description":"Outcome of treatment will be measured by self report questionnaire, the Night Eating Symptom Scale ( higher score indicates worse symptoms). The percentage of calories consumed after dinner was estimated by recall at each treatment visit, as compared to their baseline % of intake after dinner, which was calculated through food diaries. The number of nocturnal ingestions (waking during the night and eating) per week was also recalled at each treatment visit.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.1","spread":"3.0"},{"groupId":"OG001","value":"11.8","spread":"2.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":"3.5"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Nocturnal Ingestions","description":"Number of nocturnal ingestions (waking and having something to eat) were reported at each visit.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"0.5"},{"groupId":"OG001","value":"0.0","spread":"0.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"0.6"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Night Eating Symptoms","description":"The responses on the Night Eating Symptom Scale (NESS) will be examined over time.\n\nSubjects will complete the NESS at their baseline visit, and at every treatment visit thereafter. The Night Eating Symptom Scale-II (NESS-II) (Lundgren, Allison, Vinai, \\& Gluck, 2012) is a 14-item questionnaire (possible range of 0-56, with higher scores indicating more severe symptoms) that assesses the presence of NES features over the course of the previous week. The NESS will indicate whether or not escitalopram is having an effect on our participants' night eating symptoms.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.2","spread":"1.3"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":"1.5"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":31},"commonTop":["nausea","drowsiness","dry mouth","increased sweating","impotence/low libido"]}}}